Comparative evaluation of quality of life in patients with schizophrenia treated with conventional versus atypical neuroleptics: Results of a transversal study;Évaluation comparative de la qualité de vie de patients schizophrènes traités par neuroleptiques classiques et neuroleptiques atypiques: Résultats d'une étude transversale

Encephale

Volumn 32, Issue 4 I, 2006, Pages 459-465

  Divanon, F ^a   Delamillieure, P ^a,b   Lehaguez, A ^a   Vasse, T ^a   Morello, R ^a   Gourevitch, R ^c   Langlois, S ^d   Assouly Besse, F ^e   Guelfi, J D ^c   Petit, M ^d   Dollfus, S ^a,b  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b Centre Cyceron   (France)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

^d CHS du Rouvray   (France)

^e CENTRE HOSPITALIER RENÉ DUBOS   (France)

Author keywords

Antipsychotic drugs; Psychiatric assessment scale; Qualify of life; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; CYAMEMAZINE; FLUPENTIXOL; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PIMOZIDE; PIPOTIAZINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; FRANCE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PARKINSONISM; PATIENT ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; WORLD HEALTH ORGANIZATION; CROSS-SECTIONAL STUDY; MIDDLE AGED; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; STATISTICAL ANALYSIS;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SCHIZOPHRENIA;

EID: 33748279454     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0013-7006(06)76187-5     Document Type: Article

References (41)

1. ABBADI-SIMON S, GOUREVITCH R, GUELFI JD. Outils d'évaluation de la qualité de vie. Encycl Méd Chir (Elsevier, Paris) Psychiatrie 2000 ; 37,200 (A15) : 8.
2. AMERICAN PSYCHIATRIC ASSOCIATION, DSM IV. Diagnostic and Statistical Manual of mental disorders, 4 edition. Washington, DC : American Psychiatric Press, 1994.
3. ARANA GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000 ; 61 (Suppl 8) : 5-11.
4. BEASLEY CM, HAMILTON SH, CRAWFORD AM et al. Olanzapine versus haloperidol : acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997 ; 7 : 125-37.
5. BRET MC, BRET P, BONNET F. Le point sur les antipsychotiques atypiques. Pharm Hosp 2003 ; 38 : 5-29.
6. CARRIERE P, BONHOMME D, LEMPERIÈRE T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia : results of a multicentre, double-blind study. Eur Psychiatry 2000 ; 15 : 321-9.
7. CHAMBON O, MARIE-CARDINE M, COTTRAUX J et al. Impact d'un programme global d'entraînement aux habiletés sociales sur le fonctionnement social et la qualité de vie subjective de schizophrènes. Ther Comp Cogn 1995 ; 5 : 37-43.
8. CHOUINARD G, ROSS-CHOUINARD A, ANNABLE L et al. Extrapyramidal rating scale. Can J Neurol Sci 1980 ; 7 : 233.
9. CLERVOY P, CORCOS M. Epidemiology and natural history of schizophrenia. Rev Prat 2002 ; 52 : 1177-82.
10. CORTEN P. Le concept de «qualité de vie» vu à travers la littérature anglo-saxonne. Inform Psychiatr 1998 ; 9 : 922-32.
11. DENIKER P, LEMPERIÈRE T, GUYOTAT J. Précis de psychiatrie clinique de l'adulte. Paris : Masson, 1990.
12. DIAMOND R. Drugs and the quality of life : the patient's point of view. J Clin Psychiatry 1985 ; 46 : 29-35.
13. FRANZ M, LIS S, PLUDDEMANN K et al. Conventional versus atypical neuroleptics : subjective quality of life in schizophrenic patients. Br J Psychiatry 1997 ; 170 : 422-5.
14. GOUREVITCH R, ABBADI S, GUELFI JD. Quality of life in schizophrenics with and without the deficit syndrome. Eur Psychiatry 2004 ; 19 : 172-4.
15. GUELFI JD. La mesure de la qualité de vie. Ann Med Psychol 1992 ; 150 : 671-7.
16. HAMILTON SH, REVICKI DA, GENDUSO LA et al. Olanzapine versus placebo and haloperidol : quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998 ; 18 : 41-9.
17. HAMILTON SH, REVICKI DA, EDGELL ET et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics 1999 ; 15 : 469-80.
18. HUDSON TJ, SULLIVAN G, FENG W et al. Economic evaluations of novel antipsychotic medications : a literature review. Schizophr Res 2003 ; 60 : 199-218.
19. JONES P, CANNON M. The new epidemiology of schizophrenia. Psychiatr Clin North Am 1998 ; 21 : 1-25.
20. KANE J, HONIGFELD G, SINGER J et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 ; 45 : 789-96.
21. KAROW A, NABER D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002 ; 162 : 3-10.
22. KAY SR, FISZBEIN A, OPLER LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987 ; 13 : 261-76.
23. KIRKPATRICK B, BUCHANAN RW, McKENNEY PD et al. The schedule for the deficit syndrome : an instrument for research in schizophrenia. Psychiatr Res 1989 ; 30 : 119-23.
24. LANCON C, AUQUIER P, LAUNOIS R et al. Évaluation de la qualité de vie des patients schizophrènes : validation de la version courte de la QOLI. Encéphale 2000 ; 26 : 11-6.
25. LEHMAN AF, WARD NC, LINN LS. Chronic mental patients : the quality of life issue. Am J Psychiatry 1982 ; 139 : 1271-6.
26. LEHMAN AFA. Quality of Life Interview for the chronically mentally ill (QOLI). Eval Prog Planning 1988 ; 11 : 51-62.
27. LE PEN C, LILLIU H, ALLICAR MP et al. Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France. Encéphale 1999 ; 25 : 281-6.
28. MALM U, MAY P, DENICKER S. Evaluation of the quality of life of the schizophrenic outpatient : a checklist. Schizophr Bull 1981 ; 7 : 477-84.
29. MARTIN P. Le concept de qualité de vie. Act Med Int 1999 ; 16 : 4-15.
30. MONTES JM, CIUDAD A, GASCON J et al. EFESO Study Group. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia : a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 2003 ; 27 : 667-74.
31. NABER D. Long-term phase of schizophrenia : impact of atypical agents. Int Clin Psychopharmacol 2000 ; 15 (Suppl 4) : S11-4.
32. REVICKI DA, GENDUSO LA, HAMILTON SH et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders : quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 1999 ; 8 : 417-26.
33. REVICKI DA. The new atypical antipsychotics : a review of pharmacoeconomic studies. Expert Opin Pharmacother 2000 ; 1 : 249-60.
34. RIBEYRE JM, DOLLFUS S, LESIEUR P et al. Instrument d'évaluation du syndrome déficitaire de la schizophrénie : Schedule for Deficit Syndrome (SDS) (Kirkpatrick et al.). Intérêt et pertinence de la SDS. Encéphale 1994 ; 20 : 413-9.
35. ROSSLER W, SALIZE HJ, CUCCHIARO G et al. Does the place of treatment influence the quality of life of schizophrenics ? Acta Psychiatr Scand 1999 ; 100 : 142-8.
36. ROUILLON F, DANSETTE GY, LE FLOCH C. Étude de la prise en charge thérapeutique des schizophrènes et de son coût. Encéphale 1994 ; 20 : 303-9.
37. ROUILLON F, TOUMI M, DANSETTE GY et al. Some aspects of the cost of schizophrenia in France. Pharmacoeconomics 1997 ; 11 : 578-94.
38. SIMEONI MC, AUQUIER P, LANCON C et al. Revue critique des instruments de mesure de la qualité de vie dans la schizophrénie. Encéphale 2000 ; 26 : 35-41.
39. TEMPIER R, PAWLIUK N. Influence of novel and conventional antipsychotic medication on subjective quality of life. J Psychiatr Neurosci 2001 ; 26 : 131-6.
40. VORUGANTI LNP, HESLEGRAVE RJ, AWAD AG. Quality of life measurement during antipsychotic drug therapy of schizophrenia. J Psychiatr Neurosci 1997 ; 22 : 267-74.
41. VORUGANTI L, CORTESE L, OYEWUMI L et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000 ; 43 : 135-45.